US independent pharmacy | See the work behind the margin

The buyer we envisage is an owner, managing pharmacist or small-group operating lead deciding where to spend scarce management attention. A useful first question is whether one recurring exception deserves a process change, a supplier discussion or better documentation. The incentive is a more credible decision about staff time and working capital. It is not a promise that software can renegotiate a payer contract or rescue every unprofitable prescription.

We propose beginning with one owner-approved operational question and a defined historical sample. The pharmacy would select a short list of frequently investigated products or transaction exceptions. Inputs could include authorised aggregate dispensing counts, purchase records and staff estimates of resolution effort. Identifiable patient data would not be the default requirement. The study would first test whether these records can be reconciled well enough to support the chosen question.

The comparator should be the owner’s existing spreadsheet, reporting tool or manual review. Both approaches would receive the same frozen sample and the same question. We would measure preparation time, unresolved record mismatches, explanations that a pharmacist can verify and decisions requiring another source. A short independent review of disputed examples would prevent speed from hiding errors. Clinical suitability and dispensing responsibility would remain with the appropriate professionals.

We would stop or narrow the study if invoices cannot be matched to the selected products, remittances are incomplete, the owner cannot authorise the required data or the review adds more work than it removes. Apparent opportunities that depend on unverified reimbursement assumptions would remain unconfirmed. A useful negative finding might be that a better extract from the existing system solves the problem more cheaply than a new product.

A next phase would require a repeatable question, an accountable user and evidence that the output changes a real management decision. The commercial discussion would concern a defined review service or controlled software evaluation, with delivery cost and review effort made visible. One pharmacy’s result would not become a national savings claim. Expansion to a small group would require a fresh check of contracts, systems and local working practices.

Bring the decision you need to make, the person accountable for it and the evidence you can use. We can then discuss whether a bounded PHARMORIS evaluation is the right next step.